

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN: 1109-6535

Volume 5, 2008

INDEX

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
- S. Aaronson** Derarld H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA
- R. Abagyan** The Scripps Research Institute, La Jolla, CA, USA
- F. Ahmed** Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
- J.D. Aitchison** Institute for Systems Biology, Seattle, WA, USA
- W. Ansorge** IAET, Borex, Switzerland
- S. Antonarakis** Division of Medical Genetics, University of Geneva Medical School, Switzerland
- F.G. Barr** Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
- A.M. Burger** Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
- A.M. Chinnaiyan** Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
- B.F.C. Clark** Department of Molecular Biology, University of Aarhus, Denmark
- R. Clarke** Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
- I. Dunham** The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK
- N.A. Ellis** Department of Medicine University of Chicago, IL, USA
- J.A. Fernandes-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA
- C.V. Forst** McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA
- M. Fountoulakis** F. Hoffman-La Roche Pharmaceutical Research, Basel, Switzerland
- W.L. Gerald** Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J.W. Gray** Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA
- B.B. Haab** Van Andel Research Institute, Grand Rapids, MI, USA
- C.-H. Heldin** Ludwig Institute for Cancer Research, Uppsala, Sweden
- J.D. Hoheisel** Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
- R.P. Huang** Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA
- T.H.M. Huang** Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
- Y. Ito** Institute of Molecular and Cell Biology, Oncology Research Institute, Yon Loo Lin School of Medicine, National University of Singapore, Singapore
- V.C. Jordan** Fox Chase Cancer Center, Philadelphia, PA, USA
- J. Ju** Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
- A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
- O.P. Kallioniemi** Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
- M. Kanehisa** Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan
- S.E. Kern** Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA
- K. Khalili** College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- D.G. Kieback** Department of Obstetrics and Gynecology, HELIOS Medical Center, Carl Gustav Carus University, Dresden, Germany
- S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- B. Léylard-Jones** Winship Cancer Center, Emory University School of Medicine, Atlanta, GA, USA
- P. Lichter** Deutsches Krebsforschungszentrum, Heidelberg, Germany
- A. Lindblom** Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
- G. Lubec** Department of Pediatrics, University of Vienna, Austria
- J. Lyons-Weiler** Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
- P.J. McCormick** The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
- F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden
- P. Nelson** Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- C. Nicot** Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
- L. O'Driscoll** School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland

R. Ohlsson	Department of Development and Genetics, Evolution Biology Center, Uppsala University, Sweden
I. Pastan	Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA
C.D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
G. Rechavi	Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
Y. Sakaki	Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
S.W. Scherer	The Hospital for Sick Children, Department of Genetics, University of Toronto, ON, Canada
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
Y. Shimonishi	Nagahama Institute of Bioscience and Technology, Shiga, Japan
K.K. Singh	Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY, USA
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
D. Sudar	Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA, USA
A.-C. Syvänen	Department of Medical Sciences, Uppsala University Hospital, Sweden
K. Tanaka	Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
L.-C. Tsui	The Hospital for Sick Children, University of Toronto, ON, Canada
A. Ullrich	Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, Germany
G.F. Vande Woude	Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA
D.K. Watson	Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
I.B. Weinstein	Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
K. Williams	Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA
A.T. Yeung	Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Road,

P.O. Box 22, Kapandriti, Attiki, 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org; www.cgp-journal.com

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org; editor@cgp-journal.com

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 5, 2008.

Akademisch Ziekenhuis Maastricht, The Netherlands

Biochemistry and Biotechnology Facility, Fox Chase
Cancer Center, Philadelphia, PA, U.S.A.

Biomedical Mass Spectrometry Facility, Harbor UCLA,
Harbor-UCLA General Clinical Research Center, Los
Angeles, CA, U.S.A.

Cancer Foundation for South-West Finland
Chulabhorn Research Institute, Bangkok, Thailand
City of Hope Cancer Center, Duarte, CA, U.S.A.
Commonwealth of Pennsylvania, Philadelphia, PA, U.S.A.
Council for Tobacco Research

Department of Oncology, Uppsala University Hospital,
Sweden
Deutsche German Academic Exchange Service (DAAD)
Deutsche Krebshilfe
Dietmar-Hopp-Stiftung, St. Leon-Rot, Germany
Dublin City University's Research Fellowship, Ireland

European Commission

Fannie E. Rippel Foundation, Basking Ridge, NJ, U.S.A.
Finnish Cancer Foundation

German Ministry for Research and Education (BMBF)
Gobierno de Navarra, Department of Health, Spain

Ireland's Higher Educational Authority Programme for
Research in Third Level Institutions (PRTL) Cycle 3

Knut and Alice Wallenberg Foundation, Sweden
Kresge Foundation, Troy, MI, U.S.A.

La Ligue Nationale Française de Lutte Contre le Cancer,
France

Les Comité du Puy-de-Dôme et du Cantal, France

March of Dimes Birth Defects Foundation, White Plains,
NY, U.S.A.

Mitchell Cancer Institute, U.S.A.

National Cancer Institute (NCI), U.S.A.

National Institute on Drug Abuse (NIDA), U.S.A.

National Institutes of Health (NIH), U.S.A.

Nebraska Tobacco Settlement Biomedical Research
Program, Omaha, NE, U.S.A.

New Energy and Industrial Technology Development
Organization (NEDO), Kanagawa, Japan

Norwegian Cancer Society

Novartis, Basel, Switzerland

NY LILAC Foundation, NY, U.S.A.

NYSTAR-designated Center for Advanced Sensor
Technology, NY, U.S.A.

Pew Charitable Trust, Philadelphia, PA, U.S.A.

Prevent Cancer Foundation, Alexandria, VA, U.S.A.

Science Foundation, Ireland

Shöller Foundation, Philadelphia, PA, U.S.A.

Spanish Ministry of Health, Instituto de Salud Carlos III,
FIS

Turku University Foundation, Finland

Turku University Hospital, Finland

UCLA Clinical Nutrition Research Unit, Los Angeles,
CA, U.S.A.

Contents, Volume 5, 2008

Number 1

Global Comparative Gene Expression Analysis of Melanoma Patient Samples, Derived Cell Lines and Corresponding Tumor Xenografts. Y.-U. XI, A. RIKER, L.A. SHEVDE-SAMANT, R. SAMANT, C. MORRIS, E. GAVIN, O. FODSTAD, J. JU (<i>Mobile, AL, USA; Oslo, Norway</i>).....	1
CDH11 Expression is Associated with Survival in Patients with Osteosarcoma. G. NAKAJIMA, A. PATINO-GARCIA, SKJALG BRUHEIM, Y. XI, M.-S. JULIAN, F. LECANDA, L. SIERRASESUMAGA, C. MÜLLER, O. FODSTAD, J. JU (<i>Mobile, AL, USA; Pamplona, Spain; Oslo, Norway</i>).....	37
Simultaneous Modeling of Concentration-effect and Time-course Patterns in Gene Expression Data from Microarrays. Y.-F. BRUN, R. VARMA, S.-M. HECTOR, L. PENDYALA, R. TUMMALA, W.-R. GRECO (<i>Buffalo, NY, USA</i>)	43
Modelling Gene Regulation Networks via Multivariate Adaptive Splines. X. CHEN, H. ZHANG (<i>New Haven, CT, USA</i>).....	55
The Proteome Profile of the Human Osteosarcoma U2OS Cell Line. K.-N. NIFOROU, A.-K. ANAGNOSTOPOULOS, K. VOUGAS, C. KITTAS, V.-G. GORGOULIS, G.- T. TSANGARIS (<i>Athens, Greece</i>).....	63

Number 2

Microarray-based Expression of DNA Repair Genes Does not Correlate with Growth Inhibition of Cancer Cells by Natural Products Derived from Traditional Chinese Medicine. V.S.B. KONKIMALLA, G. WANG, B. KAINA, T. EFFERTH (<i>Heidelberg; Mainz, Germany; Detroit, MI, USA</i>)	79
Proteomic Based Identification of Manganese Superoxide Dismutase 2 (SOD2) as a Metastasis Marker for Oral Squamous Cell Carcinoma. H. YE, A. WANG, B.-S. LEE, T. YU, S. SHENG, T. PENG, S. HU, D.L. CROWE, X. ZHOU (<i>Chicago, IL; Atlanta, GA; Los Angeles, CA, USA; Guangzhou, China</i>)	85
Feasibility and Relevance of Global Expression Profiling of Gene Transcripts in Serum from Breast Cancer Patients Using Whole Genome Microarrays and Quantitative RT-PCR. L. O'DRISCOLL, E. KENNY, J.P. MEHTA, P. DOOLAN, H. JOYCE, P. GAMMELL, A. HILL, B. O'DALY, D. O'GORMAN, M. CLYNES (<i>Dublin, Ireland</i>).....	95
High-accuracy Prediction of Carcinogenicity by Global Quantitative Analysis of Post-translational Modifications in a 28-Day <i>In Vivo</i> Rat Study. H. YAMANAKA, Y. YAKABE, K. SAITO, M. SEKIJIMA, H. SATO, T. SHIRAI (<i>Saitama; Osaka; Ibaraki; Tokyo; Nagoya, Japan</i>).....	105
Galectin-3 Expression in Human Papillary Thyroid Carcinoma. P. SAWANGAREETRAKUL, C. SRISOMSAP, D. CHOKCHAICHAMNANKIT, J. SVASTI (<i>Bangkok, Thailand</i>).....	117
Protein Phosphatase and TRAIL Receptor Genes as New Candidate Tumor Genes on Chromosome 8p in Prostate Cancer. M. HORNSTEIN, M.J. HOFFMANN, A. ALEXA, M. YAMANAKA, M. MÜLLER, V. JUNG, J. RAHNENFÜHRER, W.A. SCHULZ (<i>Düsseldorf; Saarbrücken; Homburg; Dortmund, Germany</i>)	123

Number 3-4

Molecular Mechanisms of Action of Imatinib Mesylate in Human Ovarian Cancer: A Proteomic Analysis. B.B. PATEL, Y.A. HE, X.-M. LI, A. FROLOV, L. VANDERVEER, C. SLATER, R.J. SCHILDER, M. VON MEHREN, A.K. GODWIN, A.T. YEUNG (*Philadelphia, PA; Birmingham, AL, USA*) 137

Identification of F-box/LLR-repeated Protein 17 as Potential Useful Biomarker for Breast Cancer Therapy. G.G. XIAO, B.-S. ZHOU, G. SOMLO, J. PORTNOW, A. JUHASZ, F. UN, H. CHEW, D. GANDARA, Y. YEN (*Duarte, Torrance, Sacramento, CA; Omaha, NE, USA*) 151

Phosphoproteome and Transcriptome Analyses of ErbB Ligand-stimulated MCF-7 Cells. T. NAGASHIMA, M. OYAMA, H. KOZUKA-HATA, N. YUMOTO, Y. SAKAKI, M. HATAKEYAMA (*Kanagawa; Minato-ku, Tokyo, Japan*) 161

The Small Variant of the Apoptosis-associated X-Chromosome *RBM10* Gene is Co-expressed with Caspase-3 in Breast Cancer. E. MARTÍN-GARABATO, F. MARTÍNEZ-ARRIBAS, M. POLLÁN, A.R. LUCAS, J. SÁNCHEZ, J. SCHNEIDER (*Madrid, Spain*) 169

The Proteome Profile of Two Cell Lines and their Xenografts Isolated from a Patient with Clear Cell Sarcoma (Soft Tissue Melanoma). K. DIMAS, C. TSIMPLOULI, A.K. ANAGNOSTOPOULOS, L. MAHAIRA, E. ILIOPOULOU, S. PEREZ, K. VOUGAS, G.Th. TSANGARIS (*Athens, Greece*) 175

Erratum 239

Number 5

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (*Duarte, CA, USA*) 241

Comparative Clinical and Transcriptomal Profiles of Breast Cancer Between French and South Mediterranean Patients Show Minor but Significant Biological Differences. N. CHALABI, D.J. BERNARD-GALLON, Y.-J. BIGNON, THE BREAST MED CONSORTIUM: F. KWIATKOWSKI, M. AGIER, V. VIDAL, V. LAPLACE-CHABAUD, V. SYLVAIN-VIDAL, V. BERTHOLET, F. DE LONGUEVILLE, M. LACROIX, G. LECLERCQ, J. REMACLE, C. SIBILLE, N. ZAMMATEO, N. BEN JAAFAR, A. SEFIANI, K. OULDIM, A. MÉGARBANÉ, N. JALKH, W. MAHFOUDH, W. TROUDI, A. BEN AMMAR-EL GAÏED, L. CHOUCANE (*Clermont-Ferrand; Saint-Beauzire, France; Namur, Belgium; Rabat, Maroc; Bayrou, Liban; Tunis, Tunisie*) 253

Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (*Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA*) 263

Improved Effector Function of Leukemia-specific T-lymphocyte Clones Trained with AML-derived Dendritic Cells. F.R. SCHUSTER, R. BUHMANN, S. REUTHER, B. HUBNER, C. GRABRUCKER, A. LIEPERT, R. REIBKE, P. LICHTNER, T. YANG, T. KROELL, H.-J. KOLB, A. BORKHARDT, H. SCHMETZER (*Dusseldorf; Munich, Germany*) 275

Genomic Changes of the 55 kDa Subunit of DNA Polymerase ϵ in Human Breast Cancer. Q. ZHOU, R. EFFATI, K. TALVINEN, H. POSPIECH, J.E. SYVÄOJA, Y. COLLAN (*Turku; Oulu; Joensuu, Finland*) 287

Number 6

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (*Uppsala; Stockholm, Sweden*) 293

Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (*New York, NY, USA*) 301

Adenovirus-mediated Thymidine Kinase Gene Therapy and Coxsackie Adenovirus Receptor Expression in Ovarian Cancer Cells. D.G. KIEBACK (*Aue, Germany; Maastricht, The Netherlands*) 311

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Cell Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (*Kiel; Tuebingen, Germany*) 319

Prognostic Utility of Glycosyltransferase Expression in Breast Cancer. N. PATANI, W. JIANG, K. MOKBEL (*Cardiff, Wales; London, UK*) 333

Volume 5, 2008, Index 341

Subject Index

(Figures refer to page numbers)

- Adenovirus-mediated therapy, gene therapy, ovarian cancer, Coxsackie adenovirus receptor, 311
- Allelic imbalance, tumor suppressor, DNA methylation, expression microarray, real-time RT-PCR, 123
- AML, DC, T-cells, spectratyping, immunotherapy, stem cell transplantation, 275
- Angiogenesis, tissue microarray, migration, β 1 integrin, PAR1, MMP1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- Apoptosis, breast, cancer, caspase-3, RBM, Bax, CD105, 169
- Bax, breast, cancer, apoptosis, caspase-3, RBM, CD105, 169
- Biomarker, breast cancer, proteomics, 151
- Biomarker, osteosarcoma, CDH11, prognosis, 37
- Breast cancer, biomarker, proteomics, 151
- Breast cancer, DNA methylation, secondary structure, VNTR, c-Ha-ras, MspI site polymorphism, 241
- Breast cancer, DNA polymerase epsilon (ϵ), genomic changes, 287
- Breast cancer, extracellular RNA, serum, whole genome microarray, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), 95
- Breast cancer, glycosylation, prognosis, survival, recurrence, 333
- Breast cancer, microarrays, European and Mediterranean countries, clinical parameters, 253
- Breast cancer, SILAC, transcription, phosphorylation, proteome, heregulin, epidermal growth factor, ErbB, MCF-7, 161
- Breast, cancer, apoptosis, caspase-3, RBM, Bax, CD105, 169
- Cancer stem cells, prostate cancer, PC3MM2, genom-wide microarray, DAVID analysis, 301
- Cancer, breast, apoptosis, caspase-3, RBM, Bax, CD105, 169
- Caspase-3, breast, cancer, apoptosis, RBM, Bax, CD105, 169
- Cathepsin, tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, MMP1, VEGF, HuMV833, gemcitabine, 263
- CD105, breast, cancer, apoptosis, caspase-3, RBM, Bax, 169
- CDH11, osteosarcoma, biomarker, prognosis, 37
- Cell lines, clear cell sarcoma, soft tissue melanoma, malignant melanoma, xenografts, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 175
- C-Ha-ras, DNA methylation, breast cancer, secondary structure, VNTR, MspI site polymorphism, 241
- Cisplatin, microarrays, oxaliplatin, time-course, concentration-effect, 43
- Clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, xenografts, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 175
- Clinical parameters, breast cancer, microarrays, European and Mediterranean countries, 253
- Cluster analysis, DNA repair, microarray analysis, pharmacognosy, traditional Chinese medicine, 79
- Concentration-effect, microarrays, cisplatin, oxaliplatin, time-course, 43
- Connexin 43, melanoma, expression profiling, metastasis, 1
- Coxsackie adenovirus receptor, gene therapy, ovarian cancer, adenovirus-mediated therapy, 311
- DAVID analysis, cancer stem cells, prostate cancer, PC3MM2, genom-wide microarray, 301
- DC, AML, T-cells, spectratyping, immunotherapy, stem cell transplantation, 275
- 2D-DIGE, post-translational modifications, quantitative analysis, rat liver proteins, 105
- 2D-PAGE/MS, SOD2, manganese superoxide dismutase 2, oral cancer, OSCC, metastasis, proteomic biomarker, 85
- 2-DE protein database, clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, xenografts, proteomics, mass spectrometry, MALDI-MS, 175
- 2-DE protein database, osteosarcoma, U2OS, proteomics, mass spectrometry, MALDI-MS, 63
- DNA methylation, breast cancer, secondary structure, VNTR, c-Ha-ras, MspI site polymorphism, 241
- DNA methylation, tumor suppressor, allelic imbalance, expression microarray, real-time RT-PCR, 123
- DNA polymerase epsilon (ϵ), breast cancer, genomic changes, 287
- DNA repair, cluster analysis, microarray analysis, pharmacognosy, traditional Chinese medicine, 79
- Epidermal growth factor, SILAC, transcription, phosphorylation, proteome, breast cancer, heregulin, ErbB, MCF-7, 161
- ErbB, SILAC, transcription, phosphorylation, proteome, breast cancer, heregulin, epidermal growth factor, MCF-7, 161
- European and Mediterranean countries, breast cancer, microarrays, clinical parameters, 253
- Expression microarray, tumor suppressor, DNA methylation, allelic imbalance, real-time RT-PCR, 123
- Expression profiling, melanoma, connexin 43, metastasis, 1
- Extracellular RNA, breast cancer, serum, whole genome microarray, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), 95
- Galectin-1, human Protein Atlas Program, malignant melanoma, TRP-1, 293
- galectin-3, thyroid diseases, proteomics, immunodetection, papillary thyroid carcinoma, LC/MS/MS, 117
- Gemcitabine, tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, MMP1, VEGF, cathepsin, HuMV833, 263
- Gene expression, ochratoxin A, liver, HepG2, 319
- Gene therapy, ovarian cancer, adenovirus-mediated therapy, Coxsackie adenovirus receptor, 311
- Genomic changes, breast cancer, DNA polymerase epsilon (ϵ), 287
- Genom-wide microarray, cancer stem cells, prostate cancer, PC3MM2, DAVID analysis, 301
- Glycosylation, breast cancer, prognosis, survival, recurrence, 333
- HepG2, ochratoxin A, gene expression, liver, 319

- Heregulin, SILAC, transcription, phosphorylation, proteome, breast cancer, epidermal growth factor, ErbB, MCF-7, 161
- Human Protein Atlas Program, malignant melanoma, TRP-1, galectin-1, 293
- HuMV833, tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, MMP1, VEGF, cathepsin, gemcitabine, 263
- Imatinib mesylate, ovarian cancer, PDGFR, proteomics, 137
- Immunodetection, galectin-3, thyroid diseases, proteomics, papillary thyroid carcinoma, LC/MS/MS, 117
- Immunotherapy, DC, AML, T-cells, spectratyping, stem cell transplantation, 275
- β 1 Integrin, tissue microarray, angiogenesis, migration, PAR1, MMP1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- LC/MS/MS, galectin-3, thyroid diseases, proteomics, immunodetection, papillary thyroid carcinoma, 117
- Liver, ochratoxin A, gene expression, HepG2, 319
- MALDI-MS, clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, xenografts, proteomics, 2-DE protein database, mass spectrometry, 175
- MALDI-MS, osteosarcoma, U2OS, proteomics, 2-DE protein database, mass spectrometry, 63
- Malignant melanoma, clear cell sarcoma, soft tissue melanoma, cell lines, xenografts, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 175
- Malignant melanoma, human Protein Atlas Program, TRP-1, galectin-1, 293
- Manganese superoxide dismutase 2, SOD2, oral cancer, OSCC, metastasis, proteomic biomarker, 2D-PAGE/MS, 85
- MASAL, transcription factor binding sites, temporal gene expression, 55
- Mass spectrometry, clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, xenografts, proteomics, 2-DE protein database, MALDI-MS, 175
- Mass spectrometry, osteosarcoma, U2OS, proteomics, 2-DE protein database, MALDI-MS, 63
- MCF-7, SILAC, transcription, phosphorylation, proteome, breast cancer, heregulin, epidermal growth factor, ErbB, 161
- Melanoma, expression profiling, connexin 43, metastasis, 1
- Metastasis, melanoma, expression profiling, connexin 43, 1
- Metastasis, SOD2, manganese superoxide dismutase 2, oral cancer, OSCC, proteomic biomarker, 2D-PAGE/MS, 85
- Microarray analysis, cluster analysis, DNA repair, pharmacognosy, traditional Chinese medicine, 79
- Microarrays, breast cancer, European and Mediterranean countries, clinical parameters, 253
- Microarrays, cisplatin, oxaliplatin, time-course, concentration-effect, 43
- Migration, tissue microarray, angiogenesis, β 1 integrin, PAR1, MMP1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- MMP1, tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- MspI site polymorphism, DNA methylation, breast cancer, secondary structure, VNTR, c-Ha-ras, 241
- Ochratoxin A, gene expression, liver, HepG2, 319
- Oral cancer, SOD2, manganese superoxide dismutase 2, OSCC, metastasis, proteomic biomarker, 2D-PAGE/MS, 85
- OSCC, SOD2, manganese superoxide dismutase 2, oral cancer, metastasis, proteomic biomarker, 2D-PAGE/MS, 85
- Osteosarcoma, biomarker, CDH11, prognosis, 37
- Osteosarcoma, U2OS, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 63
- Ovarian cancer, gene therapy, adenovirus-mediated therapy, Cocksackie adenovirus receptor, 311
- Ovarian cancer, imatinib mesylate, PDGFR, proteomics, 137
- Oxaliplatin, microarrays, cisplatin, time-course, concentration-effect, 43
- Papillary thyroid carcinoma, galectin-3, thyroid diseases, proteomics, immunodetection, LC/MS/MS, 117
- PAR1, tissue microarray, angiogenesis, migration, β 1 integrin, MMP1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- PC3MM2, cancer stem cells, prostate cancer, genom-wide microarray, DAVID analysis, 301
- PDGFR, imatinib mesylate, ovarian cancer, proteomics, 137
- Pharmacognosy, cluster analysis, DNA repair, microarray analysis, traditional Chinese medicine, 79
- Phosphorylation, SILAC, transcription, proteome, breast cancer, heregulin, epidermal growth factor, ErbB, MCF-7, 161
- Post-translational modifications, 2D-DIGE, quantitative analysis, rat liver proteins, 105
- Prognosis, breast cancer, glycosylation, survival, recurrence, 333
- Prognosis, osteosarcoma, biomarker, CDH11, 37
- Prostate cancer, cancer stem cells, PC3MM2, genom-wide microarray, DAVID analysis, 301
- Proteome, SILAC, transcription, phosphorylation, breast cancer, heregulin, epidermal growth factor, ErbB, MCF-7, 161
- Proteomic biomarker, SOD2, manganese superoxide dismutase 2, oral cancer, OSCC, metastasis, 2D-PAGE/MS, 85
- Proteomics, breast cancer, biomarker, 151
- Proteomics, clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, xenografts, 2-DE protein database, mass spectrometry, MALDI-MS, 175
- Proteomics, galectin-3, thyroid diseases, immunodetection, papillary thyroid carcinoma, LC/MS/MS, 117
- Proteomics, imatinib mesylate, ovarian cancer, PDGFR, 137
- Proteomics, osteosarcoma, U2OS, 2-DE protein database, mass spectrometry, MALDI-MS, 63
- Quantitative analysis, 2D-DIGE, post-translational modifications, rat liver proteins, 105
- Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), breast cancer, extracellular RNA, serum, whole genome microarray, 95
- Rat liver proteins, 2D-DIGE, post-translational modifications, quantitative analysis, 105
- RBM, breast, cancer, apoptosis, caspase-3, Bax, CD105, 169
- Real-time RT-PCR, tumor suppressor, DNA methylation, allelic imbalance, expression microarray, 123
- Recurrence, breast cancer, glycosylation, prognosis, survival, 333
- Secondary structure, DNA methylation, breast cancer, VNTR, c-Ha-ras, MspI site polymorphism, 241
- Serum, breast cancer, extracellular RNA, whole genome microarray, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), 95

- SILAC, transcription, phosphorylation, proteome, breast cancer, heregulin, epidermal growth factor, ErbB, MCF-7, 161
- SOD2, manganese superoxide dismutase 2, oral cancer, OSCC, metastasis, proteomic biomarker, 2D-PAGE/MS, 85
- Soft tissue melanoma, clear cell sarcoma, malignant melanoma, cell lines, xenografts, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 175
- Spectratyping, DC, AML, T-cells, immunotherapy, stem cell transplantation, 275
- Stem cell transplantation, DC, AML, T-cells, spectratyping, immunotherapy, 275
- Survival, breast cancer, glycosylation, prognosis, recurrence, 333
- T-cells, DC, AML, spectratyping, immunotherapy, stem cell transplantation, 275
- Temporal gene expression, transcription factor binding sites, MASAL, 55
- Thyroid diseases, galectin-3, proteomics, immunodetection, papillary thyroid carcinoma, LC/MS/MS, 117
- Time-course, microarrays, cisplatin, oxaliplatin, concentration-effect, 43
- Tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, MMP1, VEGF, cathepsin, HuMV833, gemcitabine, 263
- Traditional Chinese medicine, cluster analysis, DNA repair, microarray analysis, pharmacognosy, 79
- Transcription factor binding sites, temporal gene expression, MASAL, 55
- Transcription, SILAC, phosphorylation, proteome, breast cancer, heregulin, epidermal growth factor, ErbB, MCF-7, 161
- TRP-1, human Protein Atlas Program, malignant melanoma, galectin-1, 293
- Tumor suppressor, DNA methylation, allelic imbalance, expression microarray, real-time RT-PCR, 123
- U2OS, osteosarcoma, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 63
- VEGF, tissue microarray, angiogenesis, migration, β 1 integrin, PAR1, MMP1, cathepsin, HuMV833, gemcitabine, 263
- VNTR, DNA methylation, breast cancer, secondary structure, c-Ha-ras, MspI site polymorphism, 241
- Whole genome microarray, breast cancer, extracellular RNA, serum, quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), 95
- Xenografts, clear cell sarcoma, soft tissue melanoma, malignant melanoma, cell lines, proteomics, 2-DE protein database, mass spectrometry, MALDI-MS, 175

Authors Index

(Figures refer to page numbers)

- Agier M, 253
 Agnarsdóttir M, 293
 Alexa A, 123
 Anagnostopoulos AK, 63, 175
 Ben Ammar-El Gaïed A, 253
 Ben Jaafar N, 253
 Bergqvist M, 293
 Bernard-Gallon DJ, 253
 Bertholet V, 253
 Bignon Y-J, 253
 Blank R, 319
 Blaschek W, 319
 Boesch-Saadatmandi C, 319
 Bolander E, 293
 Borkhardt A, 275
 Botchkina GI, 301
 Bruheim S, 37
 Brun Y-F, 43
 Buhmann R, 275
 Burger AM, 263
 Chalabi N, 253
 Chen X, 55
 Chew H, 151
 Chokchaichamnankit D, 117
 Chouchane L, 253
 Clark J, 241
 Clynes M, 95
 Collan Y, 287
 Crawford H, 301
 Crowe DL, 85
 De Longueville F, 253
 Dimas K, 175
 Doolan P, 95
 Dufour A, 301
 Effati R, 287
 Efferth T, 79
 Fiebig H-H, 263
 Fodstad O, 1, 37
 Frolov A, 137
 Gammell P, 95
 Gandara D, 151
 Gavin E, 1
 Godwin AK, 137
 Gorgoulis V-G, 63
 Grabrucker C, 275
 Greco W-R, 43
 Hatakeyama M, 161
 He YA, 137
 Hector S-M, 43
 Hesselius P, 293
 Hill A, 95
 Hoffmann MJ, 123
 Hornstein M, 123
 Hu S, 85
 Hubner B, 275
 Hundhausen C, 319
 Iliopoulou E, 175
 Jalkh N, 253
 Jiang W, 333
 Joyce H, 95
 Ju J, 1, 37, 301
 Juhasz A, 151
 Julian M-S, 37
 Jung V, 123
 Kaina B, 79
 Kenny E, 95
 Kieback DG, 311
 Kittas C, 63
 Kolb H-J, 275
 Konkimalla VSB, 79
 Kozuka-Hata H, 161
 Kroell T, 275
 Kwiatkowski F, 253
 Lacroix M, 253
 Lang F, 319
 Laplace-Chabaud V, 253
 Lecanda F, 37
 Leclercq G, 253
 Lee B-S, 85
 Li X-M, 137
 Lichtner P, 275
 Liepert A, 275
 Lucas AR, 169
 Mahaira L, 175
 Mahfoudh W, 253
 Martínez-Arribas F, 169
 Martín-Garabato E, 169
 Matzner N, 319
 Mehta JP, 95
 Mokbel K, 333
 Morris C, 1
 Müller C, 37
 Müller M, 123
 Mégarbané A, 253
 Nagashima T, 161
 Nakajima G, 37
 Niforou K-N, 63
 O'Daly B, 95
 O'Driscoll L, 95
 O'Gorman D, 95
 Ouldim K, 253
 Oyama M, 161
 Patani N, 333
 Patel BB, 137
 Patino-Garcia A, 37
 Pendyala L, 43
 Peng T, 85
 Perez S, 175
 Pollán M, 169
 Ponten F, 293
 Portnow J, 151
 Pospiech H, 287
 Rahnenführer J, 123
 Reibke R, 275
 Remacle J, 253
 Reuther S, 275
 Riker A, 1
 Rimbach G, 319
 Rowehl RA, 301
 Saito K, 105
 Sakaki Y, 161
 Samant R, 1
 Sato H, 105
 Sawangaretrakul P, 117
 Schilder RJ, 137
 Schmetzer H, 275
 Schneider J, 169
 Schulz WA, 123
 Schuster FR, 275
 Sefiani A, 253
 Sekijima M, 105
 Sheng S, 85
 Shevde-Samant LA, 1
 Shirai T, 105
 Sibille C, 253
 Sierrasesumaga L, 37
 Slater C, 137
 Smith SS, 241
 Smith V, 263
 Somlo G, 151
 Srisomsap C, 117
 Strömberg S, 293
 Svasti J, 117
 Sylvain-Vidal V, 253
 Syväoja JE, 287
 Sánchez J, 169
 Talvinen K, 287
 Troudi W, 253
 Tsangaris GT, 63, 175
 Tsimplouli C, 175
 Tummlala R, 43
 Uhlen M, 293
 Un F, 151
 Vanderveer L, 137
 Varma R, 43
 Vidal V, 253
 Von Mehren M, 137
 Vougas K, 63, 175
 Wang A, 85
 Wang G, 79
 Wirth GJ, 263
 Wolfram S, 319
 Xi Y, 1, 37
 Xiao GG, 151
 Yakabe Y, 105
 Yamanaka H, 105
 Yamanaka M, 123
 Yang T, 275
 Ye H, 85
 Yen Y, 151
 Yeung AT, 137
 Yu T, 85
 Yumoto N, 161
 Zammateo N, 253
 Zhang H, 55
 Zhou B-S, 151
 Zhou Q, 287
 Zhou X, 85

Errata

Volume 5 (2008), No 1, Contents (page 37):
The name of the second author should be:

A. PATINO-GARCIA

Volume 5 (2008), No 2, page 105:
The last author's affiliation should change:

TOMOYUKI SHIRAI⁵

Volume 5 (2008), No 5, page 253:
The authors and their affiliations should read:

N. CHALABI^{1,2}, D.J. BERNARD-GALLON^{1,2}, Y.-J. BIGNON^{1,2,3} and THE BREAST MED CONSORTIUM:
F. KWIATKOWSKI¹, M. AGIER^{1,4}, V. VIDAL^{1,4}, V. LAPLACE-CHABAUD^{1,4}, V. SYLVAIN-VIDAL^{1,4},
V. BERTHOLET⁵, F. DE LONGUEVILLE⁵, M. LACROIX⁵, G. LECLERCQ⁵, J. REMACLE⁵, C. SIBILLE⁶,
N. ZAMMATEO⁶, N. BEN JAAFAR⁷, A. SEFIANI⁷, K. OULDIM⁷, A. MÉGARBANÉ⁸, N. JALKH⁸,
W. MAHFOUDH⁹, W. TROUDI⁹, A. BEN AMMAR-EL GAÏED⁹ and L. CHOUCANE¹⁰

¹Département d'Oncogénétique, Centre Jean Perrin, 63011 Clermont-Ferrand Cedex 01;

²Centre de Recherche en Nutrition Humaine (CRNH), 63009 Clermont-Ferrand Cedex 01;

³Université d'Auvergne, 63001 Clermont-Ferrand 1;

⁴Diagnogène, Division d'Imaxio, Biopôle Clermont-Limagne, 63360 Saint-Beauzire, France;

⁵Université de Namur, URBC, 5000 Namur;

⁶Eppendorf Array Technologies, 5000 Namur, Belgium;

⁷Département de Génétique et de Biologie Moléculaire, Institut National d'Hygiène, Rabat, Maroc;

⁸Unité de Génétique Médicale, Université Saint-Joseph, Bayrou, Liban;

⁹Laboratoire d'Immunologie, Institut Pasteur de Tunis;

¹⁰Laboratoire d'Immuno-Oncologie Moléculaire,

Faculté de Médecine de Monastir, Université de Monastir, Tunis, Tunisie

CANCER GENOMICS & PROTEOMICS supports (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IAR and the Conferences please visit our websites: www.cgp-journal.com, www.iar-anticancer.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: journals@iar-anticancer.org (Editorial Office), editor@iar-anticancer.org (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription (print and online) Rates 2004, 2005, 2006, 2007, 2008: Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. Prices include rapid delivery and insurance.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece, and should be sent to the Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.